⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11877992 | 0.94 | — | — | |
| SCHEMBL11880644 | 0.92 | — | — | |
| SCHEMBL11882002 | 0.89 | TSHR (0.53) | — | |
| SCHEMBL5048 | 0.87 | — | — | |
| SCHEMBL5160680 | 0.77 | — | — | |
| SCHEMBL73367 | 0.77 | — | — | |
| SCHEMBL467961 | 0.77 | — | — | |
| SCHEMBL9225512 | 0.69 | TSHR (0.82) | — | |
| SCHEMBL328907 | 0.69 | TSHR (0.82) | — | |
| SCHEMBL11691617 | 0.69 | TSHR (0.82) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107490-A1 | HETEROCYCLE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023091229-A1 | SMALL MOLECULE BINDERS OF THE ONCOGENIC FUSION TRANSCRIPTION FACTOR PAX3-FOXO1 | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-25 | — | — | WO | claimed |
| EP-3924340-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2021-12-22 | — | — | EP | claimed |
| EP-3890716-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| EP-3849536-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3849537-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3849534-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3849538-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3849535-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3844151-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-07-07 | — | — | EP | claimed |
| WO-2005085239-A2 | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | claimed |
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| WO-2004101554-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479678-A1 | Pyrazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | claimed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | claimed |
| WO-2003090680-A2 | NOVEL PHENYL DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | claimed |
| WO-2002100849-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | claimed |